Tics and other stereotyped movements as side effects of pharmacological treatment

International Review of Neurobiology

Volumn 112, Issue , 2013, Pages 481-494

  Madruga Garrido, Marcos ^a   Mir, Pablo ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Antipsychotics; Psychostimulants; Stereotyped movements; Tardive; Tics

Indexed keywords

ANTICONVULSIVE AGENT; ATOMOXETINE; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; CLONIDINE; CLOZAPINE; DEXAMPHETAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; ETIRACETAM; FLUPHENAZINE; HALOPERIDOL; LAMOTRIGINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; PHENOBARBITAL; PHENYTOIN; PSYCHOSTIMULANT AGENT; QUETIAPINE; RESERPINE; RISPERIDONE; TETRABENAZINE; TOPIRAMATE;

AKATHISIA; ANXIETY; APPETITE DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL FEATURE; DIZZINESS; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; EPILEPSY; GILLES DE LA TOURETTE SYNDROME; GROWTH DISORDER; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; MOOD DISORDER; MOTOR DYSFUNCTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; RISK FACTOR; SEIZURE; SIDE EFFECT; TACHYCARDIA; TARDIVE DYSKINESIA; TARDIVE TOURETTISM; TIC;

ANTIPSYCHOTICS; PSYCHOSTIMULANTS; STEREOTYPED MOVEMENTS; TARDIVE; TICS;

CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; STEREOTYPIC MOVEMENT DISORDER; TICS;

EID: 84888414542     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-411546-0.00016-0     Document Type: Chapter

References (37)

1. Albin R.L. Neurobiology of basal ganglia and Tourette syndrome: Striatal and dopamine function. Advances in Neurology 2006, 99:99-106.
2. Bassitt D., Neto M. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. European Archives of Psychiatry and Clinical Neuroscience 1998, 248:209-211.
3. Blanchet P.J. Antipsychotic drug-induced movement disorders. The Canadian Journal of Neurological Science 2003, 30(Suppl. 1):S101-S107.
4. Bloch M.H., Panza K.E., Landeros-Weisenberger A., Leckman J.F. Meta-Analysis: Treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. Journal of American Academy of Child and Adolescent Psychiatry 2009, 48:884-893.
5. Burd L., Kerbeshian J., Fisher W., Gascon G. Anticonvulsant medications: An iatrogenic cause of tic disorders. Canadian Journal of Psychiatry 1986, 31:419-423.
6. Caligiuri M.P., Jeste D.V., Lacro J.P. Antipsychotic induced movement disorder in the elderly. Epidemiology and treatment recommendations. Drugs & Aging 2000, 17:363-384.
7. Chen J.J., Ondo W.G., Dashtipour K., Swope D.M. Tetrabenazine for the treatment of hyperkinetic movement disorders: A review of the literature. Clinical Therapeutics 2012, 34:1487-1504.
8. Cortese S., Holtmann M., Banaschewski T., Buitelar J., Coghill D., Danckaerts M., et al. Practitioner review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. Journal of Child Psychology and Psychiatry 2013, 54:227-246.
9. Fernandez H.H., Friedman J.H. Classification and treatment of tardive syndromes. The Neurologist 2003, 9:16-27.
10. Feroz-Nainar C., Roy M. Risperidone and late onset tics. Autism 2006, 10:302-307.
11. Fountoulakis K.N., Samara M., Siapera M., Iacovides A. Tardive Tourette-like syndrome: A systematic review. International Clinical Psychopharmacology 2011, 26:237-242.
12. Greil W., Haag H., Rossnagl G., Ruther E. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. The British Journal of Psychiatry 1984, 145:304-310.
13. Holtmann M., Korn-Merker E., Boenigk H.E. Carbamazepine induced combined phonic and motor tic in a boy with Down's syndrome. Epileptic Disorders 2000, 2:39-40.
14. Jankovic J. TouretteD́s syndrome. The New England Journal of Medicine 2001, 345:1184-1192.
15. Jankovic J., Jimenez-Shahed J., Brown L.W. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. Journal of Neurology, Neurosurgery and Psychiatry 2010, 81:70-73.
16. Klawans H.L., Falk D.K., Nausieda P.A., Weiner W.J. Gilles de la Tourette syndrome after long-term chlorpromazine therapy. Neurology 1978, 28:1064-1066.
17. Leach M.J., Marden C.M., Miller A.A. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug. II. Neurochemical studies on the mechanism of action. Epilepsia 1986, 27:490-497.
18. Lombroso C.T. Lamotrigine-induced tourettism. Neurology 1999, 52:1191-1194.
19. Louza M.R., Bassitt D.P. Maintenance treatment of severe tardive dyskinesia with clozapine: Five years follow-up. Journal of Clinical Psychopharmacology 2005, 25:180-182.
20. Martinez-Granero M.A., Garcia-Perez A., Montañes F. Levetiracetam as an alternative therapy for Tourette syndrome. Neuropsychiatric Disease and Treatment 2010, 6:309-316.
21. Mejia N.I., Jankovic J. Secondary tics and tourettism. Revista Brasileira de Psiquiatria 2005, 27:11-17.
22. Musiek E.S., Anderson C.T., Dahodwala N.A., Pollard J.R. Facial tic associated with lamotrigine in adults. Movement Disorders 2010, 25:1512-1513.
23. Neglia J.P., Glaze D.G., Zion T.E. Tics and vocalizations in children treated with carbamazepine. Pediatrics 1984, 73:841-844.
24. Poncin Y., Sukhodolsky D.G., Macguire J., Scahill L. Drug and non-drug treatments of children with ADHD and tic disorders. European Child & Adolescent Psychiatry 2007, 16(Suppl. 1):S78-S88.
25. Pringsheim T., Doja A., Belanger S., Patten S. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. Journal of Paediatrics and Child Health 2011, 16:590-598. The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) Guideline Group.
26. Pringsheim T., Doja A., Gorman D., McKinlay D., Day L., Billinghurst L., et al. Canadian guidelines for the evidence-based treatment of tic disorders: Pharmacotherapy. Canadian Journal of Psychiatry 2012, 57:133-143.
27. Pringsheim T., Steeves T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database of Systematic Reviews 2011, (4):CD007990. 10.1002/14651858.CD007990.pub2.
28. Robertson P.L., Garofalo E.A., Silverstein F.S., Komaynski M.A. Carbamazepine-induced tics. Epilepsia 1993, 34:965-968.
29. Roessner V., Robatzek M., Knapp G., Banaschewski T., Rothenberger A. First-onset tics in patients with attention-deficit-hyperactivity disorder: Impact of stimulants. Developmental Medicine and Child Neurology 2006, 48:616-662.
30. Rothenberger A., Roessner V., Banaschewski T., Leckman J.F. Co-existence of tic disorders and attention-deficit/hyperactivity disorder-recent advances in understanding and treatment. European Child & Adolescent Psychiatry 2007, 16(Suppl. 1):S1-S4.
31. Saifee T.A., Edwards M.J. Tardive movement disorders: A practical approach. Practical Neurology 2011, 11:341-348.
32. Sotero de Menezes M.A., Rho J.M., Murphy P., Cheyette S. Lamotrigine-induced tic disorder: Report of five pediatric cases. Epilepsia 2000, 41:862-867.
33. Spindler M.A., Galifianakis N.B., Wilkinson J.R., Duda J.E. Globus pallidus interna deep brain stimulation for tardive dyskinesia: Case report and review of the literature. Parkinsonism & Related Disorders 2013, 19:141-147.
34. Stahl S.M. Tardive Tourette syndrome in an autistic patient after long-term neuroleptic administration. American Journal of Psychiatry 1980, 137:1267-1269.
35. Teo J.T., Edwards M.J., Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: A hypothesis. Movement Disorders 2012, 27:1205-1215.
36. Waln O., Jankovic J. An update on tardive dyskinesias: From phenomenology to treatment. Tremor and Other Hyperkinetic Movements 2013, 3:1-11. pii: tre-03-161-4138-1.
37. Wilens T.E. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology 2008, 28:S46-S53.